Gonorrhea: Market View, Current and Future Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
This report provides a data-driven overview of the current and future competitive landscape in Gonorrhea Therapeutics.
– In 2025, there were more than 2.75 million diagnosed incident cases of GC in the 16 countries covered in GlobalData’s epidemiology forecast.
– The GC market remains largely generic, with approved treatments spanning several antibiotic classes including penicillin antibiotics, sulfonamides, fluoroquinolones, tetracyclines, azalide derivatives, aminopenicillins, and macrolides.
– Treatment has evolved from fluoroquinolone monotherapy to ceftriaxone–azithromycin dual therapy and, since 2020, ceftriaxone 500 mg IM monotherapy, which remains the recommended first-line treatment in 2026.
– Newly approved oral agents GSK’s Blujepa (gepotidacin) and Innoviva’s Nuzolvence (zoliflodacin) expand options and may help address AMR, but are currently limited to uncomplicated urogenital GC.
– The GC pipeline holds 42 molecules with no assets in the Pre-registration and Phase II stages, two assets in Phase III development, and three assets in Phase I development.
– Over the past decade, 404 clinical trials have been conducted in GC. The year with the most studies initiated was 2018, with 75 trials, followed by 2021.
– Over the past 10 years, acquisitions dominated GC product deals in South America (100.0%), Asia-Pacific (56.4%), Europe (41.5%), North America (37.8%), and the Middle East and Africa (27.3%). Licensing was most common in the Middle East and Africa (36.4%), while mergers were concentrated in North America (13.3%), Asia-Pacific (6.4%), and Europe (3.8%); none were recorded in South America or the Middle East and Africa.
– Key opinion leaders agree that expanded screening has shifted gonorrhea diagnoses toward asymptomatic disease, creating persistent diagnosis-to-treatment delays across care settings. While ceftriaxone remains trusted for high cure rates (95–98%), its intramuscular administration severely limits treatment convenience, and existing oral alternatives provide inadequate efficacy and coverage.
– Consequently, clinicians emphasize an urgent need for an affordable, single-dose oral regimen delivering at least 95% efficacy across all anatomical sites to outrun inevitable antimicrobial resistance. Beyond therapeutics, experts identify rapid, resistance-predicting point-of-care diagnostics and effective partner treatment as critical structural priorities to prevent reinfection and curb transmission.
Scope
GlobalData’s Gonorrhea: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
– Disease Landscape
– Disease Overview
– Epidemiology Overview
– Treatment Overview
– Marketed Products Assessment
– Breakdown by Mechanism of Action, Molecule type
– Product Profiles with Sales Forecast
– Pricing and Reimbursement Assessment
– Annual Therapy Cost
– Time to Pricing and Time to Reimbursement
– Pipeline Assessment
– Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
– Product Profiles with Sales Forecast
– Late-to-mid-stage Pipeline Drugs
– Phase Transition Success Rate and Likelihood of Approval
– Clinical Trials Assessment
– Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
– Enrolment Analytics, Site Analytics, Feasibility Analysis
– Deals Landscape
– Mergers, Acquisitions, and Strategic Alliances by Region
– Overview of Recent Deals
– Commercial Assessment
– Key Market Players
– Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Gonorrhea Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Reflux Esophagitis (Gastroesophageal Reflux Disease)Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Gonorrhea: Market View, Current and Future Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Gonorrhea reports